Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750302 | 0.95 | ENPP2 (0.74) | ENPP2HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL18044833 | 0.93 | ENPP2 (0.72) | ENPP2HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL18070823 | 0.92 | ENPP2 (0.67) | ENPP2HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL18070816 | 0.92 | ENPP2 (0.67) | ENPP2HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL16750182 | 0.92 | ENPP2 (0.81) | ENPP2HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL16750178 | 0.88 | ENPP2 (1.00) | ENPP2HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL16750306 | 0.88 | ENPP2 (1.00) | ENPP2HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL18070805 | 0.88 | ENPP2 (0.61) | ENPP2HDAC6HDAC1HDAC2HDAC10 | |
| SCHEMBL18070814 | 0.88 | ENPP2 (0.60) | ENPP2HDAC6 | |
| SCHEMBL16760778 | 0.88 | ENPP2 (0.98) | ENPP2HDAC6HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ATXCO, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ATXCO, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9926318-B2 | Tetracyclic autotaxin inhibitors | PHARMAKEA, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926318-B2 | Tetracyclic autotaxin inhibitors | PHARMAKEA, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | DF 2024 IP ACQUISITION, LLC | 2016-09-15 | — | — | US | disclosed |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | DF 2024 IP ACQUISITION, LLC | 2016-09-15 | — | — | US | disclosed |
| WO-2016028686-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | PHARMAKEA, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| US-9051320-B1 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor | PHARMAKEA, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051320-B1 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor | PHARMAKEA, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2015077502-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | PHARMAKEA, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, UACA | ENPP2 1/4885HDAC6 195/4885HDAC1 1017/4885 |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, UACA | ENPP2 1/4885HDAC6 195/4885HDAC1 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.